3 phases will be conducted simultaneously with commercial supply
The third vaccine after’Sputnik V’and’Epibakcorona’
viewer
viewer
Russia has officially approved the third novel coronavirus infectious disease (Corona 19) vaccine’Kobibak’ developed by itself.
Russian Prime Minister Mikhail Mischstein announced the approval of Kobibak at the meeting on vaccines on the 20th (local time) and said that the first production volume of 120,000 doses will be available in the market in the middle of next month. Kobibak is an inactivated vaccine developed by the Chumakov Immunology Research and Development Center under the Russian Academy of Sciences, and produces antibodies in the body by injecting a virus that has removed its ability to replicate into the human body. The Russian government is planning to conduct phase 3 clinical trials (Phase 3) with commercial supply after approval of Kobibak.
Prime Minister Mischstein stressed that Russia is the only country to have developed three types of COVID-19 vaccines to date. Health Minister Mikhail Murashko also explained at a press conference that Kobibak proved efficacy and safety in a clinical trial for volunteers.
Russia previously approved the world’s first COVID-19 vaccine’Sputnik V’developed by the’Gamalea National Center for Infectious Diseases and Microbiology’ under the Ministry of Health in August last year, but unlike the usual development procedure, it approved immediately after phases 1 and 2 before phase 3 Controversy arose over the efficacy and safety of the vaccine. In October last year, two vaccines for’Epibakcorona’ developed by’Bector’, a national virus and biotechnology research center under the’Consumer Rights Protection and Welfare Supervision’ (Rosport Revnadzor), a local health, hygiene, and quarantine authority. Approved for the second time. It was also an approval made after two phases.
/ Reporter Kwak Yoon-ah [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >